SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, today announced several key appointments to the company’s management. Daniel H. Petree of P2 Partners, LLC has been elected to the Sutro board of directors. The company has also named Henry Heinsohn, former senior scientist in process development at Genentech, as vice president of development and manufacturing, and Lesley Stolz, Ph.D., former vice president, corporate and business development at Sunesis Pharmaceuticals, as vice president of business development.
